I
Intermolecular
High productivity combinatorial (hpc) technology products and services for a wide range of industries
About Intermolecular
Intermolecular, Inc. operates as a crucial partner in the materials innovation sector, specializing in the exploration, testing, and development of advanced materials that underpin next-generation electronics. The company was founded in 2004 by David Lazovsky, who brought extensive experience from the semiconductor equipment industry, having previously worked at Applied Materials. His background in semiconductor technology directly informed Intermolecular's approach to accelerating research and development through a combination of proprietary high-throughput combinatorial processing tools and advanced data analytics. This methodology allows for the rapid testing of a vast number of material combinations, significantly reducing the time and cost associated with bringing new materials to market.
The firm's business model is centered on providing services to semiconductor and electronics manufacturers, helping them overcome complex materials challenges. Intermolecular's core offering is its High-Throughput Experimentation (HTE) platform, which integrates hardware, software, and data analytics to streamline the materials discovery process. Clients leverage this platform to accelerate their own R&D cycles, improve device performance, and secure intellectual property. Revenue is primarily generated through collaborative development programs and licensing of its technology and intellectual property. This approach positions the company as an external R&D arm for its clients, offering specialized expertise and infrastructure that might be prohibitive to develop in-house.
A significant milestone in the company's history was its acquisition by Merck KGaA, Darmstadt, Germany, in 2019, for approximately $62 million. This transaction transformed Intermolecular into the Silicon Valley science hub for Merck's Performance Materials business, now part of its Electronics division. The acquisition was a strategic move by Merck to bolster its capabilities in data analytics and materials informatics, particularly for the electronics industry. For Intermolecular, becoming part of a global science and technology company provided access to greater resources and a broader market, allowing it to continue breaking boundaries in materials science while contributing to Merck's larger mission of advancing digital living.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2004
- Headquarters
- San Jose, United States
- Listing
- IPO 2011
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- CCCMEA Capital
U.S. Venture Partners
Redpoint
Series B and later1 investor entered at this stage
Symyx
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intermolecular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intermolecular on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.